華神科技(000790.SZ):擬不超1.3億元購置商業資產建設華神生命養護中心項目
格隆匯1月26日丨華神科技(000790.SZ)公佈,公司於2022年1月25日召開第十二屆董事會第十七次會議,會議審議通過了《關於子公司擬購置商業資產建設華神海口生命養護中心項目的議案》。
為保障公司生命養護業務戰略落實及海南華神健康戰略佈局進一步推進實施,公司下屬全資子公司海南華神生命養護科技有限公司擬使用自有資金或其他合法自籌資金購置由海南永業投資有限公司開發的海口市美蘭區“濱江海岸”(3號樓)商業綜合體,用於公司在海口市建設全週期生命養護中心,包括醫美及健康管理等大健康產業綜合運營。商業資產產權面積約為7960平方米,總成交價格不超過1.3億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.